Thursday 7 June 2018
07:15-08:15
Amphitheatre		Inflammation in cystic fibrosis: the next frontier
Moderator: Stuart Elborn, London, UK
07:15 – 07:30 Pathophysiology of lung inflammation in CF – Marcus Mall, Berlin, DE 
07:30 –07:45Clinical trials addressing CF inflammation and their limitations – Jennifer Taylor-Cousar, Denver, US
07:45 – 08:00Current approaches – Design of acebilustat phase 2b study (EMPIRE CF) – Steven M. Rowe, Birmingham, US 
08:00 – 08:15Discussion and questions & answers
 Thursday 7 June 2018
12:30-14:00
Blue Hall		Shifting the paradigm in cystic fibrosis management: current and future
Moderator: Marcus Mall, Berlin, DE
12:30 – 12:45 Welcome and introduction – Marcus Mall, Berlin, DE
12:45 –13:05Cystic fibrosis: navigating the disease trajectory – Claire Wainwright, Brisbane, AU
13:05 – 13:25Current and future management strategies: the evidence – Jane Davies, London, UK
13:25 – 13:45Future thinking: assessing effectiveness in practice – Barry Plant, Cork, IE
13:45 – 14:00Questions & moderator’s close
Friday 8 June 2018
12:30-14:00
Amphitheatre		Making a difference in cystic fibrosis daily challenges
Moderator: Harry Heijerman, Utrecht, NL    
12:30 – 13:00 Preventing CF complications – Harry Heijerman, Utrecht, NL
13:00 –13:30Nebulized antibiotic therapy – yesterday and nowadays – Carsten Schwarz, Berlin, DE
13:30 – 14:00Dealing with the challenges of an ageing CF population – Stuart Elborn, London, UK
 Friday 8 June 2018
12:30-13:30
Annex B		From bench to bedside: Exploring in vitro to in vivo correlation of CF models
Moderator: Mark Higgins, London, UK
12:30 – 12:40 Welcome and introduction – Mark Higgins, London, UK
12:40 –13:15

Rationale, science, and robustness of CF in vitro assays to identify responsive mutations – Paul Negulescu, San Diego, USA

Does improved CFTR function in vitro translate into improvement in clinical outcomes? - Charlotte McKee, San Diego, USA

13:15 – 13:30Questions & moderator’s close